Brief: Sensus Healthcare Q2 Net Income USD -1.037 Million

Sensus Healthcare

07/08/2025 21:22

Overview

Sensus Healthcare Q2 revenue falls to $7.3 mln, missing analyst expectations

Adjusted EBITDA for Q2 was negative $1.8 mln, missing analyst estimates

Company reported a net loss of $1.0 mln, or $0.06 per share

Outlook

Company expects Medicare fee schedule changes to impact SRT adoption in 2026

Result Drivers

REVENUE DECLINE - Revenue fell due to fewer unit sales to a large customer, partially offset by growth in recurring revenue from Fair Deal Agreements

INCREASED FDA VOLUME - FDA treatment volume rose 27% sequentially, indicating traction in this area

STRATEGIC PARTNERSHIP - Partnership with Radiology Oncology Systems aims to boost distribution in hospital systems and oncology departments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$7.32 mln
$9.30 mln (5 Analysts)
Q2 Net Income
-$1.04 mln
Q2 Adjusted EBITDA
Miss
-$1.78 mln
$1.12 mln (2 Analysts)
Q2 Basic EPS
-$0.06
Q2 Operating Expenses
$4.85 mln
Q2 Pretax Profit
-$1.76 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Sensus Healthcare Inc is $11.00, about 51.5% above its August 6 closing price of $5.33

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw1JLl9Za

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)